LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

Sektor Tervishoid

7.95 5.72

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.45

Max

8.16

Põhinäitajad
By Trading Economics
Aktsiakasum	-0.172
Kasumimarginaal	-66.092
Töötajad	536

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+111.17 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2024

Turustatistika
By TradingEconomics
Turukapital	41M 990M
Eelmine avamishind	2.23
Eelmine sulgemishind	7.95

Uudiste sentiment

By Acuity

93%

3 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

6.1 / 7.65 Toetus ja vastupanu

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. okt 2024, 21:55 UTC

Suurimad hinnamuutused turgudel

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders -- Update

22. okt 2024, 21:48 UTC

Peamised uudised

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders -- Update

22. okt 2024, 21:37 UTC

Suurimad hinnamuutused turgudel

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

22. okt 2024, 21:30 UTC

Suurimad hinnamuutused turgudel

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders

22. okt 2024, 21:12 UTC

Peamised uudised

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders

22. okt 2024, 20:52 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance After Sales Slump Persists

22. okt 2024, 20:49 UTC

Peamised uudised

Tulu

Canadian National Railway Posts Higher Revenue, Lower Profit in 3Q

22. okt 2024, 20:28 UTC

Tulu

Texas Instruments Posts Lower 3Q Revenue

22. okt 2024, 23:24 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance as Sales Slump Persists -- 2nd Update

22. okt 2024, 22:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. okt 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

22. okt 2024, 22:46 UTC

Peamised uudised

Meta Bans Accounts That Track Celebrity Jet Travel, Including for Zuckerberg -- WSJ

22. okt 2024, 22:45 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 3rd Update

22. okt 2024, 21:58 UTC

Peamised uudised

Tulu

Starbucks Suspends Guidance as Sales Slump Persists -- Update

22. okt 2024, 21:53 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 2nd Update

22. okt 2024, 21:19 UTC

Peamised uudised

Texas Instruments' Guidance Falls Short. The Stock Is Rising Anyway. -- Barrons.com

22. okt 2024, 21:14 UTC

Peamised uudised

Tulu

3M Produces Beat-and-Raise Earnings. The Stock Dropped. -- Barrons.com

22. okt 2024, 21:05 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- Update

22. okt 2024, 20:55 UTC

Tulu

Philip Morris International Stock Surges to Record -- WSJ

22. okt 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

22. okt 2024, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. okt 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. okt 2024, 20:48 UTC

Peamised uudised

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- WSJ

22. okt 2024, 20:45 UTC

Peamised uudised

Treasury Yields Rise, S&P 500 Edges Lower After Earnings Flurry -- WSJ

22. okt 2024, 20:45 UTC

Tulu

GE Aerospace Stock Skids Amid Commercial-Engine Concerns -- WSJ

22. okt 2024, 20:34 UTC

Peamised uudised

Tulu

Starbucks Stock Drops After Company Misses Earnings, Suspends Guidance -- Barrons.com

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q U.S. Drilling Lower 48 Avg Rig Count of Approximately 68 Rigs >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects Full-Yr Cap Expenditures of Approximately $600M, With $230M for the SANAD Newbuilds >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q International Avg Rig Count of Approximately 84 Rigs >NBR

22. okt 2024, 20:22 UTC

Tulu

Nabors: Expects 4Q Cap Expenditures of $230M, With $105M for the Newbuilds in Saudi Arabia >NBR

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

111.17% tõus

12 kuu keskmine prognoos

Keskmine 15.88 USD 111.17%

Kõrge 30 USD

Madal 7 USD

Põhineb 8 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

6.1 / 7.65Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

3 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.